Epigenetic modification and therapeutic targets of diabetes mellitus

Shivani Chandel; Dhritiman Dey; Arijit Ghosh; Syamal Roy; Velayutham Ravichandiran; Dipanjan Ghosh

doi:10.1042/bsr20202160

journal article Open Access Sep 01, 2020

Epigenetic modification and therapeutic targets of diabetes mellitus

Shivani Chandel Dhritiman Dey Arijit Ghosh

Syamal Roy Velayutham Ravichandiran Dipanjan Ghosh

Bioscience Reports Vol. 40 No. 9 · Portland Press Ltd.

View at Publisher Save 10.1042/bsr20202160

Abstract

Abstract
The prevalence of diabetes and its related complications are increasing significantly globally. Collected evidence suggested that several genetic and environmental factors contribute to diabetes mellitus. Associated complications such as retinopathy, neuropathy, nephropathy and other cardiovascular complications are a direct result of diabetes. Epigenetic factors include deoxyribonucleic acid (DNA) methylation and histone post-translational modifications. These factors are directly related with pathological factors such as oxidative stress, generation of inflammatory mediators and hyperglycemia. These result in altered gene expression and targets cells in the pathology of diabetes mellitus without specific changes in a DNA sequence. Environmental factors and malnutrition are equally responsible for epigenetic states. Accumulated evidence suggested that environmental stimuli alter the gene expression that result in epigenetic changes in chromatin. Recent studies proposed that epigenetics may include the occurrence of ‘metabolic memory’ found in animal studies. Further study into epigenetic mechanism might give us new vision into the pathogenesis of diabetes mellitus and related complication thus leading to the discovery of new therapeutic targets. In this review, we discuss the possible epigenetic changes and mechanism that happen in diabetes mellitus type 1 and type 2 separately. We highlight the important epigenetic and non-epigenetic therapeutic targets involved in the management of diabetes and associated complications.

Topics

No keywords indexed for this article. Browse by subject →

References

186

[1]

Diabetes and Atherosclerosis

Joshua A. Beckman, Mark A. Creager, Peter Libby

JAMA 2002 10.1001/jama.287.19.2570

[2]

Ziyadeh "Overview: combating diabetic nephropathy" J. Am. Soc. Nephrol. (2003) 10.1097/01.asn.0000065608.37756.58

[3]

Fong "Diabetic retinopathy" Diabetes Care (2003) 10.2337/diacare.26.1.226

[4]

Natarajan "Lipid inflammatory mediators in diabetic vascular disease" Arterioscler. Thromb. Vasc. Biol. (2004) 10.1161/01.atv.0000133606.69732.4c

[5]

Vincent "Biology of diabetic neuropathy" Handb. Clin. Neurol. (2013) 10.1016/b978-0-444-52902-2.00034-5

[6]

Forbes "Mechanisms of diabetic complications" Physiol. Rev. (2013) 10.1152/physrev.00045.2011

[7]

Brownlee "Biochemistry and molecular cell biology of diabetic complications" Nature (2001) 10.1038/414813a

[8]

Kato "Diabetic nephropathy—emerging epigenetic mechanisms" Nat. Rev. Nephrol. (2014) 10.1038/nrneph.2014.116

[9]

Transcriptome Analysis of Human Diabetic Kidney Disease

Karolina I. Woroniecka, Ae Seo Deok Park, Davoud Mohtat et al.

Diabetes 2011 10.2337/db10-1181

[10]

Bird "Perceptions of epigenetics" Nature (2007) 10.1038/nature05913

[11]

Kato "Diabetic nephropathy—emerging epigenetic mechanisms" Nat. Rev. Nephrol. (2014) 10.1038/nrneph.2014.116

[12]

Clouaire "Methyl-CpG binding proteins: specialized transcriptional repressors or structural components of chromatin?" Cell. Mol. Life Sci. (2008) 10.1007/s00018-008-7324-y

[13]

Hakonarson "Genome-wide association studies (GWAS): impact on elucidating the aetiology of diabetes" Diabetes Metab. Res. Rev. (2011) 10.1002/dmrr.1221

[14]

Forlenza "The epidemic of type 1 diabetes: what is it telling us?" Curr. Opin. Endocrinol. (2011) 10.1097/med.0b013e32834872ce

[15]

Genomic DNA methylation: the mark and its mediators

Robert J. Klose, Adrian P. Bird

Trends in Biochemical Sciences 2006 10.1016/j.tibs.2005.12.008

[16]

Weber "Distribution, silencing potential and evolutionary impact of promoter DNA methylation in the human genome" Nat. Genet. (2007) 10.1038/ng1990

[17]

Majumder "DNA methylation dysregulates and silences the HLA-DQ locus by altering chromatin architecture" Genes Immun. (2011) 10.1038/gene.2010.77

[18]

Jerram "The genetic architecture of type 1 diabetes" Genes (2017) 10.3390/genes8080209

[19]

Zullo "Epigenetics and type 1 diabetes: mechanisms and translational applications" Transl. Res. (2017) 10.1016/j.trsl.2017.05.002

[20]

Wang "Beyond genetics: what causes type 1 diabetes" Clin. Rev. Allergy Immunol. (2017) 10.1007/s12016-016-8592-1

[21]

Fradin "Association of the CpG methylation pattern of the proximal insulin gene promoter with type 1 diabetes" PLoS ONE (2012) 10.1371/journal.pone.0036278

[22]

Olsen "Circulating differentially methylated amylin DNA as a biomarker of β-cell loss in type 1 diabetes" PLoS ONE (2016) 10.1371/journal.pone.0152662

[23]

Belot "CpG methylation changes within the IL2RA promoter in type 1 diabetes of childhood onset" PLoS ONE (2013) 10.1371/journal.pone.0068093

[24]

Taudt "Genetic sources of population epigenomic variation" Nat. Rev. Genet. (2016) 10.1038/nrg.2016.45

[25]

Allis "The molecular hallmarks of epigenetic control" Nat. Rev. Genet. (2016) 10.1038/nrg.2016.59

[26]

Rose "Understanding the relationship between DNA methylation and histone lysine methylation" Biochim. Biophys. Acta Gene Regul. Mech. (2014) 10.1016/j.bbagrm.2014.02.007

[27]

Gowher "Mammalian DNA methyltransferases: new discoveries and open questions" Biochem. Soc. Trans. (2018) 10.1042/bst20170574

[28]

Miao "Profiles of epigenetic histone post-translational modifications at type 1 diabetes susceptible genes" J. Biol. Chem. (2012) 10.1074/jbc.m111.330373

[29]

Miao "Lymphocytes from patients with type 1 diabetes display a distinct profile of chromatin histone H3 lysine 9 dimethylation: an epigenetic study in diabetes" Diabetes (2008) 10.2337/db08-0645

[30]

Hezova "microRNA-342, microRNA-191 and microRNA-510 are differentially expressed in T regulatory cells of type 1 diabetic patients" Cell. Immunol. (2010) 10.1016/j.cellimm.2009.10.012

[31]

Roggli "Involvement of microRNAs in the cytotoxic effects exerted by proinflammatory cytokines on pancreatic β-cells" Diabetes (2010) 10.2337/db09-0881

[32]

Roggli "Changes in microRNA expression contribute to pancreatic β-cell dysfunction in prediabetic NOD mice" Diabetes (2012) 10.2337/db11-1086

[33]

Nielsen "Circulating levels of microRNA from children with newly diagnosed type 1 diabetes and healthy controls: evidence that miR-25 associates to residual beta-cell function and glycaemic control during disease progression" Exp. Diabetes Res. (2012) 10.1155/2012/896362

[34]

Torres "Genome wide association studies for diabetes: perspective on results and challenges" Pediatr. Diabetes (2013) 10.1111/pedi.12015

[35]

Hattersley "The diagnosis and management of monogenic diabetes in children and adolescents" Pediatr. Diabetes (2009) 10.1111/j.1399-5448.2009.00571.x

[36]

Grant "Can the genetics of type 1 and type 2 diabetes shed light on the genetics of latent autoimmune diabetes in adults?" Endocr. Rev. (2010) 10.1210/er.2009-0029

[37]

Gillespie "Type 1 diabetes: pathogenesis and prevention" CMAJ (2006) 10.1503/cmaj.060244

[38]

Erlich "HLA DR-DQ haplotypes and genotypes and type 1 diabetes risk: analysis of the type 1 diabetes genetics consortium families" Diabetes (2008) 10.2337/db07-1331

[39]

Sanjeevi "Effects of the second HLA-DQ haplotype on the association with childhood insulin-dependent diabetes mellitus" Tissue Antigens (1995) 10.1111/j.1399-0039.1995.tb02434.x

[40]

Pugliese "HLA-DQB1* 0602 is associated with dominant protection from diabetes even among islet cell antibody-positive first-degree relatives of patients with IDDM" Diabetes (1995) 10.2337/diab.44.6.608

[41]

Hathout "Clinical, autoimmune, and HLA characteristics of children diagnosed with type 1 diabetes before 5 years of age" Pediatrics (2003) 10.1542/peds.111.4.860

[42]

Todd "Robust associations of four new chromosome regions from genome-wide analyses of type 1 diabetes" Nat. Genet. (2007) 10.1038/ng2068

[43]

Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls

Paul R. Burton, David G. Clayton, Lon R. Cardon et al.

Nature 2007 10.1038/nature05911

[44]

Grant "Follow-up analysis of genome-wide association data identifies novel loci for type 1 diabetes" Diabetes (2009) 10.2337/db08-1022

[45]

Barrett "Genome-wide association study and meta-analysis find that over 40 loci affect risk of type 1 diabetes" Nat. Genet. (2009) 10.1038/ng.381

[46]

Mohlke "What will diabetes genomes tell us?" Curr. Diabetes Rep. (2012) 10.1007/s11892-012-0321-4

[47]

Hu "What have we learned from six years of GWAS in autoimmune diseases, and what is next?" Curr. Opin. Immunol. (2012) 10.1016/j.coi.2012.09.001

[48]

Bradfield "A genome-wide meta-analysis of six type 1 diabetes cohorts identifies multiple associated loci" PLoS Genet. (2011) 10.1371/journal.pgen.1002293

[49]

Nejentsev "Rare variants of IFIH1, a gene implicated in antiviral responses, protect against type 1 diabetes" Science (2009) 10.1126/science.1167728

[50]

Senée "Mutations in GLIS3 are responsible for a rare syndrome with neonatal diabetes mellitus and congenital hypothyroidism" Nat. Genet. (2006) 10.1038/ng1802

Showing 50 of 186 references

Cited By

67

Metabolic memory: mechanisms and diseases

Hao Dong, Yuezhang Sun · 2024

Signal Transduction and Targeted Th...

Astragalus polysaccharide improve the proliferation and insulin secretion of mouse pancreatic β cells induced by high glucose and palmitic acid partially through promoting miR-136-5p and miR-149-5p expression

Shifang Deng, Lei Yang · 2021

Bioengineered

Metrics

67

Citations

186

References

Details

Published: Sep 01, 2020
Vol/Issue: 40(9)
License: View

Authors

S

Shivani Chandel